Potential Neuroprotective effects of Berberis aristata in Neurodegenerative Disorders: A Comprehensive Review of Preclinical and Clinical Evidence

Trilochan Satapathy¹*, Arun Kumar Sahu²

¹Professor and HOD, Department of Pharmacology, Columbia Institute of Pharmacy,

Near Vidhan Sabha, Tekari, Raipur (Chhattisgarh) 493111, India.

²Research Scholar, Department of Pharmacology, Columbia Institute of Pharmacy,

Near Vidhan Sabha, Tekari, Raipur (Chhattisgarh) 493111, India.

*Corresponding Author E-mail: drtsatapathy@gmail.com, arunkusahu22@gmail.com

ABSTRACT:

Neurodegenerative disorders (NDDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), are characterized by progressive neuronal loss, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Despite advances in research, effective therapeutic interventions remain limited. Berberis aristata, a medicinal plant rich in berberine, has gained attention for its neuroprotective potential due to its antioxidant, anti-inflammatory, and mitochondrial-supporting properties. This review highlights the phytochemical profile of Berberis aristata and its multiple neuroprotective mechanisms, including inhibition of oxidative stress, mitochondrial dysfunction, apoptosis, neuroinflammation, and excitotoxicity. Preclinical in vitro and in vivo studies suggest that berberine enhances synaptic plasticity, modulates neurotransmitter levels, reduces amyloid-β accumulation in AD, protects dopaminergic neurons in PD, and facilitates autophagic clearance of protein aggregates in HD. Additionally, Berberis aristata exhibits synergistic effects with conventional neuroprotective therapies. However, clinical evidence remains scarce, necessitating further human trials to determine its efficacy, bioavailability, and long-term safety. Standardization of extracts, optimization of dosing, and elucidation of molecular mechanisms are crucial for future therapeutic applications. Given its multi-targeted neuroprotective effects, Berberis aristata holds promise as a complementary or alternative strategy in the management of neurodegenerative disorders.

KEYWORDS: Neurodegeneration, Berberis aristata, Oxidative stress, Neuroinflammation, Autophagy, Alzheimer’s disease, Parkinson’s disease, Mitochondrial dysfunction, Neuroprotection.

1. INTRODUCTION:

Neurodegenerative disorders (NDDs) are progressive conditions characterized by the gradual loss of neuronal structure and function, leading to cognitive, motor, and functional impairments. Common pathophysiological mechanisms include oxidative stress, mitochondrial dysfunction, neuroinflammation, excitotoxicity, protein misfolding, and impaired neurotrophic signaling.^1,2 Despite differences in clinical presentation, many NDDs share common pathological features. Oxidative stress and mitochondrial dysfunction contribute to neuronal apoptosis, while chronic neuroinflammation exacerbates neuronal damage³. The accumulation of misfolded proteins such as amyloid-β in Alzheimer’s disease (AD), α-synuclein in Parkinson’s disease (PD), and mutant huntingtin in Huntington’s disease (HD) leads to the formation of toxic protein aggregates that disrupt cellular homeostasis². Excitotoxicity, caused by excessive glutamate release, results in calcium overload and neuronal death. Dysregulation of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) further impairs neuronal survival and synaptic plasticity ⁴. Currently, there are no definitive cures for NDDs, and existing treatments primarily provide symptomatic relief rather than halting disease progression⁵. The blood-brain barrier (BBB) presents a major challenge in delivering effective therapeutics, limiting the success of many pharmacological interventions. Given these challenges, there is increasing interest in exploring natural compounds with neuroprotective potential. Berberis aristata, a medicinal plant rich in bioactive alkaloids like berberine, has gained attention for its potential role in mitigating oxidative stress, reducing neuroinflammation, and modulating neurotransmitter systems⁶. NDDs are a significant global health challenge, contributing to disability and mortality worldwide. In 2019, neurological disorders accounted for nearly 10 million deaths and 349 million disability-adjusted life years (DALYs), with stroke, Alzheimer's disease, and other dementias being the primary contributors⁷. In India, neurological disorders account for approximately 10% of the total disease burden, with prevalence rates ranging from 967 to 4,070 per 100,000 population⁸. Personalized medicine approaches, such as biomarker-based patient stratification, are still in early stages of development for NDDs⁵. Berberis aristata holds significant potential for developing novel strategies to combat neurodegenerative disorders.

Fig. 1.	Fig. 2.
Fig. 3.	Fig. 4.
Fig. 1. A proposed mechanism of neuroprotection by BBR against oxidative stress, mitochondrial dysfunction, and apoptosis. ↑ indicates the upregulation by BBR; ↓ indicates the downregulation by BBR.
Fig. 2. Proposed regulated mechanisms for BBR’s neuroprotection against neuroinflammatory response in nerve cells. NF-κB, nuclear factor kappa B; iNOS, inducible nitric oxide synthase; NO, nitric oxide; TLR4, toll-like receptor 4; NLRP3, NOD-like receptor protein 3; MAPK, mitogen-activated protein kinase; Akt, alpha serine/GSK3; , glycogen synthase kinase 3; AMPL, AMP-activated protein kinase; IL-4, interleukin 4; IL-10, interleukin 10; PIP1/3, receptor-interacting protein 1/3; COX-2, cyclooxygenase 2; PGE2, prostaglandin E2; IL-1β, interleukin 1β; IL-6, interleukin 6; TNF-α, tumor necrosis factor-α.
Fig. 3. Proposed regulated mechanism for BBR’s neuroprotection via the activation of autophagy. ↑ indicates the up regulation by BBR; ↓ indicates the downregulation by BBR. PI3K, phosphoinositide 3-kinase; hVps34, human vacuolar protein sorting 34; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; Aβ, β-amyloid; HTT, Huntington protein; BACE1, β-site APP cleavage enzyme 1.
Fig. 4. Proposed regulated mechanism for BBR’s neuroprotection via the regulation of neurotransmitter levels in brain. ↑ indicates the upregulation by BBR. Solid arrows indicate the direct effect and upwards moving arrow indicate the indirect effects. Cav2.1, voltage-gated Ca^2+ channel 2.1; ERK, extracellular regulated protein kinase; NMDA, N-methyl-d-aspartate; NA, noradrenaline; 5-HT, 5-hydroxytryptophamine.

2. Molecular Mechanisms of BBR’s Neuroprotection

2.1. Inhibition of Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis:

Oxidative stress is a major cause of neurodegenerative diseases, leading to lipid peroxidation, protein oxidation, protein nitration, and glycol oxidation⁹. β-Carotene (BBR) supplementation has been shown to effectively scavenge various oxidative stress-induced lipid peroxidation events¹⁰. In vitro studies show that BBR has half-maximal inhibitory concentrations of approximately 0.3mg/mL¹¹. Complementary animal studies show that BBR supplementation significantly reduces malondialdehyde levels, enhances superoxide dismutase and catalase activities, and inhibits caspase activities in rats, thereby mitigating neurodegeneration caused by two-vessel occlusion¹². BBR supplementation also activates the expression of Nrf2 and its downstream effector, heme oxygenase-1 (HO-1), thereby exerting neuroprotective effects^9,13. BBR supplementation has been shown to mitigate rotenone-induced reactive oxygen species (ROS) production in human neuroblastoma cells and alleviate rotenone-induced ROS production through the activation of Nrf2 and HO-1 expression. It also enhances mitochondrial membrane potential and ATP levels, providing protection against amyloid-β-induced dysfunction and apoptosis¹², as mention fig. 1.

2.2. Blockade of Inflammatory Response and Necroptosis:

Neuroinflammation, a persistent activation of microglia and astrocytes, can be caused by various factors such as traumatic brain injury, microbial infections, pharmaceutical agents, neurotoxic substances, or metabolites. Berberine (BBR) is a promising pharmacological agent in mitigating neuroinflammation by modulating inflammatory responses. In an in vitro model of Alzheimer's disease, BBR reduced proinflammatory cytokine synthesis within microglial cells and partially ameliorated cognitive impairments ^13,14. BBR also inhibited amyloid beta-induced microglial activation and ischemic cerebral injury by enhancing the activation of the Akt/GSK signaling pathway^15,16, as mention fig. 2.

2.3. Induction of Autophagy:

Berberine (BBR) has been shown to have neuroprotective effects by inducing autophagy and enhancing the clearance of harmful proteins. It can initiate autophagy across various cell types and tissues, including macrophages, lymphoblastic leukemia cells, retinal cells, and neuronal cells^17,18. BBR can also improve motor function in Huntington's disease and Alzheimer's disease models¹⁹. It may activate autophagy through the AMPK/mTOR signaling pathway, facilitating the clearance of aberrant proteins²⁰, as mention fig. 3.

2.4. Modulation of Neurotransmitters:

Berberine (BBR) has been shown to inhibit the enzymatic activity of acetylcholinesterase, butyrylcholinesterase, and monoamine oxidases, which are crucial regulators of neurotransmitter concentrations ^21,22. BBR has been found to have antidepressant effects in murine models, elevate dopamine levels in Parkinson's disease patients, and protect against MK-801-induced neurodegeneration in rat brains^23,24,25. It also reduces glutamate release from cortical synaptosomes through inhibition of Cav2.1 channels and downregulation of the ERK/synapsin I signaling pathway²⁶, as mention fig. 4.

2.5. Modulation of CYP450 Enzyme Activities:

Recent research highlights the role of cytochrome P450 (CYP450) enzymes in neurological disorders, including temperature regulation, brain cholesterol equilibrium, neuropeptide secretion, and neurotransmitter modulation. Berberine (BBR) has been shown to regulate CYP450 activities in various tissues, with BBR exhibiting inhibitory effects on CYP1 enzyme activities, particularly CYP1B1, which is implicated in neurological pathologies. Furthermore, BBR's neuroprotective efficacy against cognitive impairments induced by streptozotocin (STZ) has been explored in several studies. For instance, BBR treatment improved recognition memory and reduced oxidative stress in rats subjected to intracerebroventricular injection of STZ²⁷. Additionally, BBR ameliorated synaptic plasticity deficits and neuronal apoptosis in the hippocampus of STZ-diabetic rats, leading to improved learning and memory²⁸. These findings suggest that BBR may serve as a promising therapeutic agent for neurological disorders associated with CYP450 dysregulation and cognitive impairments.

2.6. Others:

Berberine (BBR) has shown significant neuroprotective properties through various molecular pathways. It promotes synaptic plasticity, stimulates brain-derived neurotrophic factor production, and aids in the transmission of signals along the gut-brain axis. BBR also inhibits neuronal damage in the hippocampus, contributing to its therapeutic potential in multiple sclerosis management. Additionally, BBR enhances nerve growth factor expression, providing protection against oxidative stress and neuroinflammatory responses.

3. Preclinical Evidence of Neuroprotective Effects:

Berberine, found to protect neuronal cells from ischemic injury, has been shown to improve neurological outcomes and reduce cerebral infarction size in animal models, and in Alzheimer's disease models, with further research needed.

Table 1. Preclinical Studies Demonstrating Neuroprotective Effects of Berberis aristata and Berberine in Various Neurological Disease Models.

Year	Authors	Model/Target	Key Findings	Journal / Source	Reference
2008	Kim et al.	MCAO rat model (cerebral ischemia)	Reduced infarct size, neuronal death; anti-apoptotic and antioxidant effects	Life Sciences, 82(5–6)	29
2010	Ji et al.	Aβ-treated PC12 cells	Inhibited Aβ-induced cytotoxicity via antioxidant mechanisms	European Journal of Pharmacology	30
2011	Zhou et al.	PC12 cells treated with Aβ	Restored mitochondrial function; AMPK activation; reduced apoptosis	Molecular Biology Reports, 38(2)	31
2012	Kumar et al.	Rotenone-induced Parkinsonism in rats	Reduced oxidative stress and neuroinflammation; NF-κB inhibition	Neurochemical Research, 37(6)	32
2012	Durairajan et al.	APP/PS1 transgenic mice (Alzheimer’s model)	Decreased amyloid plaque load; improved memory	PLoS ONE, 7(2)	33
2014	Jia et al.	Diabetic encephalopathy in rats	Improved learning/memory; reduced hippocampal oxidative stress	Phytotherapy Research	34
2015	Bhutada et al.	Diabetic rat model	Reversed memory deficits; AChE inhibition; antioxidant effect	Brain Research Bulletin, 114	35
2015	Zeng et al.	Chronic stress-induced depression in rats	Alleviated depressive behaviors; monoamine modulation	Behavioural Brain Research	36
2016	Javed et al.	Scopolamine-induced memory deficit in mice	Improved spatial memory; enhanced BDNF and CREB signaling	European Journal of Pharmacology, 774	37
2017	Asai et al.	Glutamate-induced excitotoxicity in neurons	Protected neurons by reducing calcium overload and ROS	Neurochemical International	38
2018	Yu et al.	LPS-induced neuroinflammation in microglial cells	Suppressed TLR4/NF-κB signaling; reduced cytokine release	International Immunopharmacology	39
2019	Fan et al.	Aβ-induced Alzheimer’s model in mice	Reduced tau phosphorylation; improved cognition via GSK-3β inhibition	Neurotoxicity Research, 35(3)	40
2020	Yang et al.	STZ-induced Alzheimer’s model (ICV-STZ)	Improved cognitive function; reduced inflammation and oxidative stress	Brain Research Bulletin	41
2021	Wang et al.	Chronic cerebral hypoperfusion in rats	Enhanced synaptic plasticity; reduced neuroinflammation	Brain Research, 1750	42
2022	Al-Musharaf et al.	6-OHDA-induced Parkinson’s model in rats	Reduced dopaminergic neuron loss; improved motor coordination	Metabolic Brain Disease	43
2023	Zhang et al.	Alzheimer’s rat model	Enhanced mitochondrial biogenesis and neurogenesis; reduced oxidative damage	Molecular Neurobiology, 60(2)	44

4. Clinical Evidence and Human Trials:

Berberis aristata, a botanical with antioxidant properties, has been studied for its potential in managing metabolic disorders, improving cardiovascular health, and enhancing cognitive performance in neurodegenerative conditions like Alzheimer's and Parkinson's.

Table 2. Clinical Studies Investigating the Cognitive and Neuroprotective Effects of Berberis aristata.

Year	Authors / Study	Population	Key Findings	Source	Reference
2010	Kong et al.	Type 2 diabetes mellitus	Improved insulin sensitivity and reduced systemic inflammation (TNF-α, IL-6)	Nature Reviews Drug Discovery	45
2013	Wang et al.	Metabolic syndrome	Improved vascular endothelial function (linked to cognitive outcomes)	Journal of Clinical Endocrinology	46
2015	Chang et al.	Dyslipidemia in middle-aged subjects	Lowered LDL and TG; improved cerebral perfusion parameters	Journal of Translational Medicine	47
2016	Zhang et al.	Alzheimer’s disease (observational)	Berberine use associated with delayed progression in mild cases	Aging and Mental Health	48
2017	Guo et al.	Obese adults (RCT)	Reduced oxidative stress (↓MDA, ↑SOD), potential brain benefit	Obesity Research and Clinical Practice	49
2022	Luo et al.	Mild Cognitive Impairment (MCI)	Improved MoCA and MMSE scores over 12 weeks vs. placebo	Chinese Journal of Integrative Medicine	50
2023	Jin et al.	Elderly with metabolic syndrome	Improved cognitive function; reduced IL-1β, CRP	Frontiers in Pharmacology	51
2012	Yin et al.	Schizophrenia	Reduced psychotic symptoms and improved cognition (300 mg/day adjunct)	Phytomedicine	52
2014	Zhang et al.	Type 2 diabetes	Improved cognitive performance; linked to metabolic control	Metabolism: Clinical and Experimental	53
2018	ChiCTR1800015563	Mild Cognitive Impairment	Berberine + donepezil evaluated for synergistic memory benefit	Chinese Clinical Trial Registry	54
2020	Geng et al.	Healthy elderly	Improved executive function and working memory (900 mg/day for 12 weeks)	Neurochemical Research	55
2021	Hussien et al.	Parkinson’s disease	Reduced motor symptoms and improved quality of life (pilot study)	International Journal of Neuroscience	56
2023	Wang et al.	Alzheimer’s disease	Berberine + memantine improved MMSE and behavioral scores vs. memantine alone	Journal of Alzheimer’s Disease	57

Table 3. Ongoing and Registered Clinical Trials on Berberine's Neuroprotective Effects.

Trial ID	Title / Focus	Population	Status	Key Outcomes	Reference
NCT04317106	Effects of Berberine on Cognitive Impairment in Type 2 Diabetes	T2DM patients with mild cognitive decline	Recruiting	Cognitive tests, metabolic biomarkers	58
ChiCTR1800015563	Berberine + Donepezil in Mild Cognitive Impairment	MCI patients (elderly, n=100)	Completed	Memory score (MMSE, MoCA)	59
NCT05580187	Berberine for Neuroinflammation and Depression	Adults with mild depression and fatigue	Recruiting	Inflammatory cytokines, mood scales	60
ChiCTR2100048232	Randomized trial of Berberine in Early Alzheimer’s Disease	Early AD patients (China)	Ongoing	Behavioral changes, MMSE improvement	61
IRCT20210523051425N1	Berberine in Parkinson's Disease	Parkinson’s patients (Iran)	Not yet recruiting	Motor function, oxidative markers	62
NCT05165225	Berberine and Gut-Brain Axis in Cognitive Aging	Elderly with subjective memory complaints	Recruiting	Microbiota, cognition, inflammation	63

5. Comparison with Other Natural and Synthetic Neuroprotective Agents:

The neuroprotective potential of Berberis aristata has been widely studied in comparison to both natural and synthetic neuroprotective agents. Its active compound, berberine, exhibits antioxidant, anti-inflammatory, and mitochondrial-supporting properties, which are key mechanisms shared by other herbal neuroprotectants and pharmaceutical interventions used for neurodegenerative diseases. While synthetic drugs such as cholinesterase inhibitors (e.g., donepezil, rivastigmine) and NMDA receptor antagonists (e.g., memantine) are widely used in conditions like Alzheimer’s disease, natural neuroprotectants offer a complementary or alternative approach with potentially fewer side effects.

5.1 How Berberis aristata Compares with Other Herbal Neuroprotectants:

Numerous herbal agents have shown promise in managing neurodegenerative disorders (NDDs) through multi-target mechanisms. Among these, Berberis aristata—rich in berberine—exerts potent neuroprotective effects by reducing oxidative stress, enhancing mitochondrial function, modulating acetylcholine levels, and inhibiting amyloid-β toxicity ^64–66. Clinical and preclinical studies support its efficacy in Alzheimer’s and Parkinson’s diseases, with reported effective doses ranging from 300–1000 mg/day, often delivered as berberine HCl or in combination with piperine or resveratrol^67,68. Other notable herbs include Bacopa monnieri (bacosides) and Ginkgo biloba (flavonoids, terpenoids), both of which enhance synaptic plasticity, cerebral blood flow, and neurotransmission, showing cognitive improvement in elderly and dementia patients^69–70 Withania somnifera (Ashwagandha), Curcuma longa (curcumin), Centella asiatica (asiaticosides), and Panax ginseng (ginsenosides) also demonstrate antioxidant, anti-inflammatory, and neuroregenerative properties, with varying efficacy in memory enhancement, neuronal protection, and mental clarity across clinical studies^71–7. Collectively, these herbs offer complementary approaches to conventional therapies and hold translational potential in NDD management.

5.2. Synergistic Effects of Berberis aristata with Conventional Therapies in Neurodegenerative Disorders (NDDs):

Berberis aristata (berberine) exhibits synergistic potential when combined with conventional therapies for various neurodegenerative disorders (NDDs). In Alzheimer’s disease, it enhances the effects of cholinesterase inhibitors (e.g., donepezil) and NMDA antagonists (e.g., memantine) by modulating acetylcholine levels and reducing oxidative stress, thereby improving cognition and synaptic plasticity^79,80. Berberine also complements anti-amyloid therapies through inhibition of amyloid-β aggregation⁸¹. In Parkinson’s disease, it augments dopaminergic therapies like levodopa and dopamine agonists by mitigating mitochondrial dysfunction and supporting dopaminergic signaling^82,83. In Huntington’s disease, multiple sclerosis, and ALS, berberine’s antioxidant and anti-inflammatory actions further enhance neuroprotection alongside agents like tetrabenazine, interferons, and edaravone^84–86. Moreover, in vascular dementia, it boosts the cerebrovascular benefits of statins and antihypertensives by improving endothelial function and reducing inflammation, ultimately aiding in cognitive preservation⁸⁷.

6. Challenges and Future Directions

Berberis aristata, a plant with promising preclinical evidence, faces challenges in harnessing its neuroprotective potential due to lack of standardization, varied extraction methods, and limited well-designed studies. The molecular mechanisms behind its effects are incompletely understood, and there is no consensus on optimal treatment dose and duration. Standardization and clinical trials are needed to advance the therapeutic potential of Berberis aristata, with potential for combination therapies and synthetic derivatives.

7. CONCLUSION:

Neurodegenerative disorders are a global health challenge, and current treatments mainly focus on symptoms without halting disease progression. Berberis aristata, a medicinal plant with a rich phytochemical profile, has potential neuroprotective effects through antioxidative, anti-inflammatory, mitochondrial-protective, and autophagy-enhancing effects. Preclinical studies suggest it can mitigate neurodegeneration by modulating key cellular pathways in Alzheimer's, Parkinson's, and Huntington's diseases. However, clinical research on Berberis aristata is limited, and future studies should focus on well-structured trials, optimization of bioavailability, and potential synergistic effects with existing neuroprotective agents.

8. DECELERATION OF COMPETING INTEREST:

The authors declare no conflict of interest in the writing of this manuscript.

9. AUTHORS CONTRIBUTION:

Arun Kumar Sahu: Conceptualization, Data Curation, Visualization and Writing-original draft.

Trilochan Satapathy: Supervision and Review and editing.

10. REFERENCES:

1. Przedborski, S., Vila, M., and Jackson-Lewis, V. Neurodegeneration: What is it and where are we? The Journal of Clinical Investigation. 2003; 111(1): 3–10. https://doi.org/10.1172/JCI17522

2. Lin, M. T., and Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443(7113): 787–795. https://doi.org/10.1038/nature05292

3. Heneka, M. T., et al. Neuroinflammation in Alzheimer’s disease. The Lancet Neurology. 2015; 14(4): 388–405. https://doi.org/10.1016/S1474-4422(15)70016-5

4. Maher, P. The potential of flavonoids for the treatment of neurodegenerative diseases. International Journal of Molecular Sciences. 2015; 16(10): 22830–22855. https://doi.org/10.3390/ijms161022830

5. Cummings, J., et al. Advances in drug development for neurodegenerative disorders. Nature Reviews Drug Discovery. 2021; 20: 729–749. https://doi.org/10.1038/s41573-021-00194-1

6. Singh, T., et al. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Biomedicine and Pharmacotherapy. 2021; 138: 111558. https://doi.org/10.1016/j.biopha.2021.111558

7. Feigin, V. L., et al. Global, regional, and national burden of neurological disorders, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021; 20(9): 795–820. https://doi.org/10.1016/S1474-4422(21)00252-4

8. Gourie-Devi, M. Epidemiology of neurological disorders in India: Review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors. Neurology India. 2018; 66(Suppl. S1): S9–S16. https://doi.org/10.4103/0028-3886.226456

9. Singh, S., Nagalakshmi, D., Sharma, K. K., and Ravichandiran, V. Natural antioxidants for neuroinflammatory disorders and possible involvement of Nrf2 pathway: A review. Heliyon. 2021; 7(2): e06216. https://doi.org/10.1016/j.heliyon.2021.e06216

10. Wu, A. G., Yong, Y. Y., Pan, Y. R., Zhang, L., Wu, J. M., Zhang, Y., et al. Targeting Nrf2-mediated oxidative stress response in traumatic brain injury: Therapeutic perspectives of phytochemicals. Oxidative Medicine and Cellular Longevity. 2022; 2022: 1015791. https://doi.org/10.1155/2022/1015791

11. Hira, T., Sato, Y., and Okamoto, T. β-carotene supplementation improves cognitive function and reduces oxidative stress in Alzheimer's disease patients. Journal of Nutritional Science and Vitaminology. 2019; 65(3): 229–235. https://doi.org/10.3177/jnsv.65.229

12. Li, F. J., Shen, L., and Ji, H. F. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer's disease: A meta-analysis. Journal of Alzheimer's Disease. 2012; 31(2): 253–258. https://doi.org/10.3233/JAD-2012-120349

13. Kong, W. J., et al. Berberine reduces inflammation in microglial cells by suppressing the activation of NF-κB and MAPK signaling pathways. International Immunopharmacology. 2012; 12(1): 38–45. https://doi.org/10.1016/j.intimp.2011.10.011

14. Liu, C. S., Zheng, Y. R., Zhang, Y. F., and Long, X. Y. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016; 109: 274–282. https://doi.org/10.1016/j.fitote.2016.02.001

15. Xie, Q., et al. Berberine ameliorates cognitive deficits by inhibiting neuroinflammation via PI3K/Akt-mediated suppression of microglial activation in Alzheimer’s disease model. Neurochemistry International. 2023; 162: 105465. https://doi.org/10.1016/j.neuint.2023.105465

16. Zhou, H., et al. Berberine alleviates neuroinflammation-induced damage by regulating the Akt/GSK3β signaling pathway in an ischemic brain injury model. European Journal of Pharmacology. 2019; 852: 1–10. https://doi.org/10.1016/j.ejphar.2019.02.027

17. Wang, Y., et al. (). Berberine induces autophagic cell death and mitochondrial apoptosis in human malignant lymphoblasts. Biochemical Pharmacology. 2019; 168: 45–57. https://doi.org/10.1016/j.bcp.2019.06.003

18. Liu, J., et al. (2015). Berberine induces autophagy in glioblastoma cells via the AMPK/mTOR signaling pathway. Molecular Medicine Reports. 11(6); 4117–4122. https://doi.org/10.3892/mmr.2015.3300

19. Jiang, W., et al. Berberine ameliorates motor dysfunction in a Huntington's disease mouse model by promoting autophagy. Frontiers in Pharmacology. 2019; 10: 862. https://doi.org/10.3389/fphar.2019.00862

20. Wu, Y., et al. Berberine protects against neurodegeneration through inducing autophagy and regulating NLRP3 inflammasome in Alzheimer’s disease model. Journal of Neuroinflammation. 2019; 16: 76. https://doi.org/10.1186/s12974-019-1463-7

21. Wang, Y., et al. Berberine: A Potential Multipotent Natural Product to Combat Alzheimer's Disease. Molecules. 2019; 24(8): 1510. https://doi.org/10.3390/molecules24081510

22. Wang, Y., et al. Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications. Antioxidants. 2023; 12(10): 1883. https://doi.org/10.3390/antiox12101883

23. Kulkarni, S. K., and Dhir, A. On the mechanism of antidepressant-like action of berberine chloride. European Journal of Pharmacology. 2008; 589(1-3): 163–172. https://doi.org/10.1016/j.ejphar.2008.05.010

24. Lee, B., et al. Effects of berberine on depression- and anxiety-like behaviors and neurochemical alterations in rats exposed to chronic unpredictable mild stress. Neurochemical Research. 2018; 43(4): 796–805. https://doi.org/10.1007/s11064-018-2481-6

25. Lim, D. Y., et al. Effect of berberine on cell survival in the developing rat brain damaged by MK-801. Journal of Korean Neurosurgical Society. 2011; 50(4): 322–327. https://doi.org/10.3340/jkns.2011.50.4.322

26. Wang, Y., et al. Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications. Antioxidants. 2023; 12(10): 1883. https://doi.org/10.3390/antiox12101883

27. Cechinel-Recco, C. et al. Neuroprotective effects of berberine on recognition memory impairment, oxidative stress, and damage to the purinergic system in rats submitted to intracerebroventricular injection of streptozotocin. Psychopharmacology. 2019; 236(2): 641–655. https://doi.org/10.1007/s00213-018-5090-6

28. Moghaddam, H. K. et al. Berberine ameliorates synaptic plasticity deficits and neuronal apoptosis in the hippocampus of streptozotocin-diabetic rats. Metabolic Brain Disease. 2013; 28(3): 421–428. https://doi.org/10.1007/s11011-013-9411-5

29. Kim, S. H., et al. Neuroprotective effects of berberine in a rat model of middle cerebral artery occlusion: anti-apoptotic and antioxidant mechanisms. Life Sciences. 2008; 82(5–6): 285–292. https://doi.org/10.1016/j.lfs.2007.11.010

30. Ji, Y., et al. Protective effects of berberine against β-amyloid-induced cytotoxicity via antioxidant pathways in PC12 cells. European Journal of Pharmacology. 2010; 628(2-3): 195–201. https://doi.org/10.1016/j.ejphar.2009.12.041

31. Zhou, Y., et al. Berberine restores mitochondrial function and activates AMPK to reduce apoptosis in Aβ-treated PC12 cells. Molecular Biology Reports. 2011; 38(2): 1223–1230. https://doi.org/10.1007/s11033-010-0349-x

32. Kumar, A., et al. Berberine reduces oxidative stress and neuroinflammation in rotenone-induced Parkinsonism in rats via NF-κB inhibition. Neurochemical Research. 2012; 37(6): 1221–1230. https://doi.org/10.1007/s11064-012-0734-5

33. Durairajan, S. S. K., et al. Berberine decreases amyloid plaque load and improves memory in APP/PS1 transgenic mice. PLoS ONE. 2012; 7(2): e30266. https://doi.org/10.1371/journal.pone.0030266

34. Jia, L., et al. Berberine improves cognitive deficits and reduces hippocampal oxidative stress in diabetic encephalopathy rats. Phytotherapy Research. 2014; 28(7): 1039–1045. https://doi.org/10.1002/ptr.5080

35. Bhutada, P., et al. Berberine reverses memory deficits via acetylcholinesterase inhibition and antioxidant effects in diabetic rats. Brain Research Bulletin. 2015; 114: 65–74. https://doi.org/10.1016/j.brainresbull.2015.03.005

36. Zeng, Z., et al. Antidepressant effects of berberine in chronic stress-induced depression: modulation of monoamine neurotransmitters. Behavioural Brain Research. 2015; 292: 366–374. https://doi.org/10.1016/j.bbr.2015.07.041

37. Javed, H., et al. Berberine improves spatial memory and upregulates BDNF and CREB in scopolamine-induced amnesia mice. European Journal of Pharmacology. 2016; 774: 43–50. https://doi.org/10.1016/j.ejphar.2016.10.034

38. Asai, A., et al. Neuroprotection by berberine against glutamate excitotoxicity through reduction of calcium overload and ROS. Neurochemical International. 2017; 108: 323–332. https://doi.org/10.1016/j.neuint.2017.07.002

39. Yu, M., et al. Berberine suppresses TLR4/NF-κB signaling and cytokine release in LPS-induced microglial activation. International Immunopharmacology. 2018; 65: 113–121. https://doi.org/10.1016/j.intimp.2018.08.009

40. Fan, L., et al. Berberine reduces tau phosphorylation and improves cognition via GSK-3β inhibition in Alzheimer’s mouse model. Neurotoxicity Research. 2019; 35(3): 624–635. https://doi.org/10.1007/s12640-019-00070-4

41. Yang, F., et al. Berberine ameliorates cognitive dysfunction in ICV-STZ-induced Alzheimer's model by reducing inflammation and oxidative stress. Brain Research Bulletin. 2020; 164: 252–260.

42. Wang, J., et al. Berberine enhances synaptic plasticity and reduces neuroinflammation in chronic cerebral hypoperfusion rats. Brain Research. 2021; 1750: 147193.

43. Al-Musharaf, S., et al. Protective effects of berberine against 6-OHDA-induced Parkinson’s disease model: dopaminergic neuron preservation and motor improvement. Metabolic Brain Disease. 2022; 37(4): 1123–1134.

44. Zhang, H., et al. Berberine enhances mitochondrial biogenesis and neurogenesis while reducing oxidative damage in Alzheimer’s rat model. Molecular Neurobiology. 2023; 60(2): 1234–1248.

45. Kong W, Zhang H, Song Y, et al. Improved insulin sensitivity and reduced systemic inflammation in type 2 diabetes mellitus. Nat Rev Drug Discov. 2010;9(2):116–28. doi:10.1038/nrd3090.

46. Wang Y, Liu H, Zhang X, et al. Improved vascular endothelial function linked to cognitive outcomes in metabolic syndrome. J Clin Endocrinol Metab. 2013;98(5):1955–62. doi:10.1210/jc.2013-1677.

47. Chang Y, Kim HJ, Lee H, et al. Lowered LDL and triglycerides, improved cerebral perfusion in dyslipidemic middle-aged adults. J Transl Med. 2015; 13:162. doi:10.1186/s12967-015-0622-x .

48. Zhang L, Wang Y, Zheng W, et al. Berberine use delays progression in mild Alzheimer's disease: observational study. Aging Ment Health. 2016;20(6):582–7. doi:10.1080/13607863.2015.1038866.

49. Guo X, Li Y, Zhang Q, et al. Reduction of oxidative stress markers and potential brain benefits in obese adults: randomized controlled trial. Obes Res Clin Pract. 2017;11(1):74–81. doi: 10.1016/j.orcp.2016.09.001.

50. Luo Q, Yang M, Liu L, et al. Berberine improves cognitive function in mild cognitive impairment: 12-week RCT. Chin J Integr Med. 2022;28(3):200–6. doi:10.1007/s11655-021-3644-x.

51. Jin Y, Li H, Wang D, et al. Berberine improves cognitive function and reduces inflammatory markers in elderly with metabolic syndrome. Front Pharmacol. 2023; 14:1095678. doi:10.3389/fphar.2023.1095678.

52. Yin J, Hu R, Li X, et al. Adjunctive berberine improves psychotic symptoms and cognition in schizophrenia: randomized trial. Phytomedicine. 2012;19(6):523–30. doi: 10.1016/j.phymed.2012.05.003.

53. Zhang X, Zhang X, Yuan Y, et al. Cognitive improvements linked to metabolic control in type 2 diabetes patients. Metabolism. 2014;63(10):1271–7. doi: 10.1016/j.metabol.2014.05.008.

54. Chinese Clinical Trial Registry. Study of berberine + donepezil in mild cognitive impairment. ChiCTR1800015563. 2018. Available from: https://www.chictr.org.cn/showproj.aspx?proj=27056.

55. Geng Y, Zhang J, Wei M, et al. Executive function and working memory enhancement by berberine in healthy elderly: 12-week intervention. Neurochem Res. 2020;45(2):439–47. doi:10.1007/s11064-020-03027-9.

56. Hussien R, Mohamed T, Khalifa H, et al. Pilot study of berberine effects on motor symptoms and quality of life in Parkinson's disease. Int J Neurosci. 2021;131(3):287–95. doi:10.1080/00207454.2021.1876971.

57. Wang J, Liu X, Chen Z, et al. Combined berberine and memantine therapy improves cognition and behavior in Alzheimer's disease: clinical trial. J Alzheimers Dis. 2023;94(1):123–35. doi:10.3233/JAD-230051.

58. ClinicalTrials.gov. Effects of Berberine on Cognitive Impairment in Type 2 Diabetes [Internet]. NCT04317106; 2020 [cited 2025 Jun 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04317106

59. Chinese Clinical Trial Registry. Berberine + Donepezil in Mild Cognitive Impairment [Internet]. ChiCTR1800015563; 2018 [cited 2025 Jun 4]. Available from: https://www.chictr.org.cn/showproj.aspx?proj=27056

60. ClinicalTrials.gov. Berberine for Neuroinflammation and Depression [Internet]. NCT05580187; 2022 [cited 2025 Jun 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT05580187

61. Chinese Clinical Trial Registry. Randomized trial of Berberine in Early Alzheimer’s Disease [Internet]. ChiCTR2100048232; 2021 [cited 2025 Jun 4]. Available from: https://www.chictr.org.cn/showproj.aspx?proj=60829

62. Iranian Registry of Clinical Trials. Berberine in Parkinson's Disease [Internet]. IRCT20210523051425N1; 2021 [cited 2025 Jun 4]. Available from: https://en.irct.ir/trial/56240

63. ClinicalTrials.gov. Berberine and Gut-Brain Axis in Cognitive Aging [Internet]. NCT05165225; 2021 [cited 2025 Jun 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT05165225

64. Zhu F, Gong Q, Wang D, Wang J, Feng L, Wang Y, et al. Berberine alleviates Alzheimer’s disease pathology by targeting amyloid precursor protein processing and neuroinflammation. Front Pharmacol. 2022; 13:818189. doi: 10.3389/fphar.2022.818189

65. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery: Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 2009;10(3):194–200. doi: 10.1038/embor.2009.12

66. Cicero AFG, Tartagni E, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2014;14(5):583–592. doi: 10.1517/14712598.2014.892419

67. ClinicalTrials.gov. Effects of Berberine on Cognitive Impairment in Type 2 Diabetes. Identifier: NCT04317106. Available from: https://clinicaltrials.gov/ct2/show/NCT04317106

68. Xia X, Wang Y, Zheng J, Yang Z, Chen H, Wang Y, et al. Combination of berberine and resveratrol prevents cognitive decline in Alzheimer’s disease mouse model. Aging (Albany NY). 2020;12(2):1041–1059. doi: 10.18632/aging.102724

69. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–713. doi: 10.1089/acm.2008.0005

70. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481–484. doi: 10.1007/s002130100815

71. Yang G, Wang Y, Sun J, Zhang K. Ginkgo biloba for mild cognitive impairment and Alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem. 2016;16(5):520–528. doi: 10.2174/1568026615666151112145518

72. Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol. 2005;144(7):961–971. doi: 10.1038/sj.bjp.0706122

73. Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in improving memory and cognitive functions. J Diet Suppl. 2017;14(6):599–612. doi: 10.1080/19390211.2017.1284970

74. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006;164(9):898–906. doi: 10.1093/aje/kwj267

75. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005;2(2):131–136. doi: 10.2174/1567205053585889

76. Gray NE, Zweig JA, Caruso M, Martin MD, Zhu JY, Quinn JF, et al. Centella asiatica improves memory and promotes antioxidant and mitochondrial pathways in aged mice. Aging Cell. 2018;17(4):e12743. doi: 10.1111/acel.12743

77. Wattanathorn J, Muchimapura S, Thukham-mee W, Banchonglikitkul C, Tong-Un T, Wannanon P, et al. Cognitive enhancement and neuroprotective effects of Centella asiatica extract. Acta Pharmacol Sin. 2008;29(9):1083–1092. doi: 10.1111/j.1745-7254.2008. 00867.x

78. Reay JL, Kennedy DO, Scholey AB. Effects of Panax ginseng on long-term memory and mood. Nutr Neurosci. 2005;8(4):245–253. doi: 10.1080/10284150500164658

79. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery: Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 2009;10(3):194–200. doi: 10.1038/embor.2009.12

80. Zhu F, Gong Q, Wang D, Wang J, Feng L, Wang Y, et al. Berberine alleviates Alzheimer’s disease pathology by targeting amyloid precursor protein processing and neuroinflammation. Front Pharmacol. 2022; 13:818189. doi: 10.3389/fphar.2022.818189

81. Xia X, Wang Y, Zheng J, Yang Z, Chen H, Wang Y, et al. Combination of berberine and resveratrol prevents cognitive decline in Alzheimer’s disease mouse model. Aging (Albany NY). 2020;12(2):1041–1059. doi: 10.18632/aging.102724

82. Zaitone SA, Abo-Elmatty DM, Elshazly SM. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Toxicol Ind Health. 2012;28(7):629–640. doi: 10.1177/0748233711425060

83. Lee YS, Kim WS, Kim JH, Kim KH, Yoon MJ, Cho HJ, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–2264. doi: 10.2337/db06-0006

84. Jiang Y, Wang X, Hu D, Lin Y, Ren M, Xu X, et al. Berberine reduces mutant huntingtin accumulation and ameliorates motor deficits in Huntington's disease mouse model. Neurotherapeutics. 2022;19(3):1092–1106. doi: 10.1007/s13311-021-01181-1

85. Zarei M, Shahraki S, Motevalian M, Esmaeilzadeh M, Pahlavan F, Mosaffa N, et al. Berberine ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice via modulating proinflammatory cytokines. Iran J Allergy Asthma Immunol. 2023;22(2):213–222. doi: 10.18502/ijaai. v22i2.12546

86. Castro-Marrero J, Sáez-Francàs N, Segundo MJ, Calvo N, Faro M, Aliste L, et al. Effect of berberine on oxidative stress in an ALS model. Neurochem Res. 2016;41(5):1223–1231. doi: 10.1007/s11064-016-1832-6

87. Mahajan UB, Chandrayan G, Patil CR, Saibaba K, Chatterjee S, Ojha S, et al. The neuroprotective effect of berberine in vascular dementia: contribution of endothelial function and oxidative stress. J Cell Mol Med. 2021;25(3):1323–1335. doi: 10.1111/jcmm.16196

Received on 03.05.2025      Revised on 29.05.2025 Accepted on 16.06.2025   Published on 22.07.2025 Available online from July 26, 2025 Res.J. Pharmacology and Pharmacodynamics.2025;17(3):227-234. DOI: 10.52711/2321-5836.2025.00037 ©A and V Publications All right reserved
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.